Drug Profile
Research programme: hippo pathway targeting anticancer therapeutics - Cancer Research Technology/Merck
Latest Information Update: 28 Jul 2021
Price :
$50
*
At a glance
- Originator Cancer Research Technology; Merck AG
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Jul 2021 No recent reports of development identified for research development in Cancer in Germany
- 28 Jul 2021 No recent reports of development identified for research development in Cancer in United Kingdom
- 29 Jun 2017 Cancer Research Technology and Merck agree to co-develop hippo pathway targeting anticancer therapeutics for Cancer